drugset / Trial / NCT02564926

Foxiga Korea Local Phase 4 Study

NCT02564926

Phase 4 Completed 125 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the effect of dapagliflozin on body composition in Korean T2DM subjects.12-month, randomised, open-label, parallel-group, multi-centre phase IV study.

Timeline

Start
2016-01-05
Primary completion
2018-01-15
Completion
2018-01-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule 10 mg
Comparator Glimepiride Small molecule 1 mg
Comparator Glimepiride Small molecule 2 mg
Background Metformin Small molecule 1000 mg